Literature DB >> 1712901

The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1.

S S Banerji1, J N Parsons, M J Tocci.   

Abstract

The macrolide FK-506, like the cyclic undecapeptide cyclosporin A (CsA), is a potent immunosuppressant that interferes with the transcriptional activation of several early-phase genes in T lymphocytes, including that for interleukin-2 (IL-2). We compared the effects of FK-506 and CsA on transcription from the 5' upstream activating sequences (UAS) of the human IL-2 gene and several cellular and viral UAS to define cis-acting sites which may be responsive to FK-506. The UAS surveyed included the human IL-2 receptor alpha-chain, human metallothionein II, simian virus 40 early, human cytomegalovirus immediate-early, adenovirus major late, and Rous sarcoma virus long terminal repeat UAS. In addition, we studied multimers of several defined promoter elements (NFIL-2A, NF-kappa B, or NF-AT1) which are found in the UAS of the human IL-2 gene and which have been reported to be responsive to CsA when linked to a minimal promoter element (TATA box and transcription start site). Each promoter-regulatory region was fused to the bacterial chloramphenicol acetyltransferase gene and used to transiently transfect Jurkat cells. Quantitative chloramphenicol acetyltransferase assay determinations indicated that the transcriptional activity of each UAS induced upon T-cell activation was (i) completely sensitive, (ii) partially sensitive, or (iii) resistant to inhibition by CsA and FK-506. The induced transcription driven by the IL-2 promoter elements NF-AT1 and NFIL-2A could be blocked completely by FK-506 or CsA. Gel mobility shift assays indicated that the binding activities of the factors specifically interacting with these sequences were detected in activated cells regardless of whether the cells were treated with FK-506 or CsA. The results suggest that FK-506 or CsA inhibits a transacting mechanism(s) without disrupting the binding activities of these transcription factors. The degree to which each UAS was resistant to FK-506 was consistent with the level of transcription induced by phorbol myristate acetate, while UAS which were sensitive to inhibition by FK-506 were dependent on the presence of both phorbol myristate acetate and ionomycin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712901      PMCID: PMC361217          DOI: 10.1128/mcb.11.8.4074-4087.1991

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  70 in total

1.  Two regions within the human IL-2 gene promoter are important for inducible IL-2 expression.

Authors:  T M Williams; L Eisenberg; J E Burlein; C A Norris; S Pancer; D Yao; S Burger; M Kamoun; J A Kant
Journal:  J Immunol       Date:  1988-07-15       Impact factor: 5.422

2.  A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase.

Authors:  M W Harding; A Galat; D E Uehling; S L Schreiber
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

3.  The NF-kappa B-binding site mediates phorbol ester-inducible transcription in nonlymphoid cells.

Authors:  B Nelsen; L Hellman; R Sen
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

4.  Promoter region of interleukin-2 gene undergoes chromatin structure changes and confers inducibility on chloramphenicol acetyltransferase gene during activation of T cells.

Authors:  U Siebenlist; D B Durand; P Bressler; N J Holbrook; C A Norris; M Kamoun; J A Kant; G R Crabtree
Journal:  Mol Cell Biol       Date:  1986-09       Impact factor: 4.272

5.  Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins.

Authors:  G Fischer; B Wittmann-Liebold; K Lang; T Kiefhaber; F X Schmid
Journal:  Nature       Date:  1989-02-02       Impact factor: 49.962

6.  T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression.

Authors:  C H June; J A Ledbetter; M M Gillespie; T Lindsten; C B Thompson
Journal:  Mol Cell Biol       Date:  1987-12       Impact factor: 4.272

7.  Cyclosporin A inhibits late steps of T lymphocyte activation after transmembrane signaling.

Authors:  Y Mizushima; H Kosaka; S Sakuma; K Kanda; K Itoh; T Osugi; A Mizushima; T Hamaoka; H Yoshida; K Sobue
Journal:  J Biochem       Date:  1987-11       Impact factor: 3.387

8.  Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin.

Authors:  N Takahashi; T Hayano; M Suzuki
Journal:  Nature       Date:  1989-02-02       Impact factor: 49.962

9.  Interleukin-1 costimulatory activity on the interleukin-2 promoter via AP-1.

Authors:  K Muegge; T M Williams; J Kant; M Karin; R Chiu; A Schmidt; U Siebenlist; H A Young; S K Durum
Journal:  Science       Date:  1989-10-13       Impact factor: 47.728

10.  The octamer-binding proteins form multi-protein--DNA complexes with the HSV alpha TIF regulatory protein.

Authors:  T M Kristie; J H LeBowitz; P A Sharp
Journal:  EMBO J       Date:  1989-12-20       Impact factor: 11.598

View more
  11 in total

1.  Differential expression of four members of the POU family of proteins in activated and phorbol 12-myristate 13-acetate-treated Jurkat T cells.

Authors:  A K Bhargava; Z Li; S M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

Review 2.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

3.  Cyclosporin A sensitivity of the NF-kappa B site of the IL2R alpha promoter in untransformed murine T cells.

Authors:  P G McCaffrey; P K Kim; V E Valge-Archer; R Sen; A Rao
Journal:  Nucleic Acids Res       Date:  1994-06-11       Impact factor: 16.971

4.  Tacrolimus ointment in the management of atopic dermatitis.

Authors:  Antonello Baldo; Mariana Cafiero; Paola Di Caterino; Luisa Di Costanzo
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-01-27

5.  Low-Dose Tacrolimus Prevents Dysregulated Peri-Conceptional Ovarian and Systemic Immune Cellular Homeostasis in Subjects with PCOS.

Authors:  Ahmad J H Albaghdadi; Carolyn Ann Feeley; Frederick W K Kan
Journal:  Sci Rep       Date:  2019-04-25       Impact factor: 4.379

6.  Protocol TOP-Study (tacrolimus organ perfusion): a prospective randomized multicenter trial to reduce ischemia reperfusion injury in transplantation of marginal liver grafts with an ex vivo tacrolimus perfusion.

Authors:  Sebastian Pratschke; Michael Eder; Michael Heise; Silvio Nadalin; Andreas Pascher; Peter Schemmer; Marcus N Scherer; Frank Ulrich; Heiner Wolters; Karl-Walter Jauch; Dirk Wöhling; Martin K Angele
Journal:  Transplant Res       Date:  2013-03-04

7.  Identification of a novel cyclosporin-sensitive element in the human tumor necrosis factor alpha gene promoter.

Authors:  A E Goldfeld; P G McCaffrey; J L Strominger; A Rao
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

8.  Activation and expression of the nuclear factors of activated T cells, NFATp and NFATc, in human natural killer cells: regulation upon CD16 ligand binding.

Authors:  J Aramburu; L Azzoni; A Rao; B Perussia
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

9.  FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells.

Authors:  L Venkataraman; S J Burakoff; R Sen
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

Review 10.  Endoplasmic Reticulum Calcium Pumps and Tumor Cell Differentiation.

Authors:  Bela Papp; Sophie Launay; Pascal Gélébart; Atousa Arbabian; Agnes Enyedi; Jean-Philippe Brouland; Edgardo D Carosella; Homa Adle-Biassette
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.